These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Designing Dual Inhibitors of Autotaxin-LPAR GPCR Axis. Banerjee S; Lee S; Norman DD; Tigyi GJ Molecules; 2022 Aug; 27(17):. PubMed ID: 36080255 [TBL] [Abstract][Full Text] [Related]
3. Development of lysophosphatidic acid pathway modulators as therapies for fibrosis. Budd DC; Qian Y Future Med Chem; 2013 Oct; 5(16):1935-52. PubMed ID: 24175745 [TBL] [Abstract][Full Text] [Related]
5. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis. Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295 [TBL] [Abstract][Full Text] [Related]
6. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Oikonomou N; Mouratis MA; Tzouvelekis A; Kaffe E; Valavanis C; Vilaras G; Karameris A; Prestwich GD; Bouros D; Aidinis V Am J Respir Cell Mol Biol; 2012 Nov; 47(5):566-74. PubMed ID: 22744859 [TBL] [Abstract][Full Text] [Related]
7. Imaging Pulmonary Fibrosis and Treatment Efficacy In Vivo with Autotaxin-Specific PET Ligand [ Deng X; Liu J; Zhou J; Shi Y; Song S; Chen J; Li Y; Yu B; Liang SH; Zhu X Mol Pharm; 2024 Oct; 21(10):5171-5181. PubMed ID: 39186477 [TBL] [Abstract][Full Text] [Related]
8. Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis: limiting fibrosis by limiting lysophosphatidic acid synthesis. Tager AM Am J Respir Cell Mol Biol; 2012 Nov; 47(5):563-5. PubMed ID: 23125419 [No Abstract] [Full Text] [Related]
9. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis. Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447 [TBL] [Abstract][Full Text] [Related]
10. Autotaxin-Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications. Laface C; Ricci AD; Vallarelli S; Ostuni C; Rizzo A; Ambrogio F; Centonze M; Schirizzi A; De Leonardis G; D'Alessandro R; Lotesoriere C; Giannelli G Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062979 [TBL] [Abstract][Full Text] [Related]
17. Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma. Onallah H; Catane LJ; Tropé CG; Hetland Falkenthal TE; Reich R; Davidson B Virchows Arch; 2018 Oct; 473(4):463-470. PubMed ID: 30032361 [TBL] [Abstract][Full Text] [Related]
18. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme. Tabuchi S Lipids Health Dis; 2015 Jun; 14():56. PubMed ID: 26084470 [TBL] [Abstract][Full Text] [Related]
19. Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways. Zhao J; He D; Berdyshev E; Zhong M; Salgia R; Morris AJ; Smyth SS; Natarajan V; Zhao Y Biochem J; 2011 Oct; 439(1):45-55. PubMed ID: 21696367 [TBL] [Abstract][Full Text] [Related]
20. A defective lysophosphatidic acid-autophagy axis increases miscarriage risk by restricting decidual macrophage residence. Yang HL; Lai ZZ; Shi JW; Zhou WJ; Mei J; Ye JF; Zhang T; Wang J; Zhao JY; Li DJ; Li MQ Autophagy; 2022 Oct; 18(10):2459-2480. PubMed ID: 35220880 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]